RSNA 2024: Transforming Breast Health through AI
The Radiological Society of North America (RSNA) 2024 Annual Meeting once again set the stage for iCAD’s impactful presence, showcasing the latest advancements in breast imaging and artificial intelligence (AI). With over 40,000 attendees—an 18% increase from the previous year—and 715 exhibitors, the event underscored the rapidly growing focus on...
ProFound Detection Version 4.0: The Next Generation in Early Breast Cancer Detection
With over 20 years of artificial intelligence innovation and experience, iCAD was the first to introduce an FDA-cleared AI solution for Digital Breast Tomosynthesis (DBT) in 2016. ProFound Detection V4.0 now extends that pioneering legacy to its fourth generation AI using the latest in deep learning neural network technologies, offering...
Revolutionizing AI Breast Cancer Detection: Speed, Scalability, and Security.
In an era where technology continuously redefines healthcare, radiologists and breast imaging professionals face the critical task of detecting breast cancer early and more accurately, avoiding the pitfalls of a missed or delayed diagnosis of cancer. Artificial intelligence (AI) is revolutionizing breast cancer detection by providing radiologists with powerful tools...
Quality Images. Precise Detection. Elevated Patient Care.
Patients are more informed than ever and are actively seeking breast health care providers who use cutting edge technology to help improve mammography quality and breast cancer screening effectiveness. As patient volumes surge and health facilities face a critical shortage of radiologists and technologists, imaging centers often face the growing...
Improve Workstation Readability with ProFound AI Detection v3 Service Pack
ProFound AI Detection delivers clarity, confidence, and peace of mind. ProFound is clinically proven to improve breast cancer detection and radiologist performance. FDA Cleared. CE Marked. Health Canada Licensed.
At ECR 2024, iCAD showed strong collaboration at European Congress: A Recap of Key Events
At this year’s European Congress of Radiology (ECR 2024) in Vienna, Austria, iCAD demonstrated how the ProFound AI Breast Health Suite enables medical providers to detect cancer earlier and more accurately, improving patient outcomes. The demonstrations highlighted the new release of its AI-powered ProFound Detection workflow solution, while showcasing its...
iCAD’s Innovative Leadership in Mammography AI Shined at RSNA 2023: A Recap of Key Events
Attendees at this year’s Radiological Society of North America (RSNA) 2023 Annual Meeting witnessed iCAD’s prominent presence, showcasing groundbreaking advancements in the field of breast imaging and artificial intelligence (AI). iCAD, a global medical technology leader in innovative cancer detection solutions, made headlines with new clinical data, shared exciting partnership...
Joining Forces with Google to Revolutionize Breast Cancer Screening Worldwide
by Dana Brown, President and CEO of iCAD, Inc. We’ve joined forces with Google Health once again to address two of the most pressing challenges in healthcare: the global radiologist shortage and significant disparities in healthcare. Per our 20-year worldwide agreement, Google’s AI technology will seamlessly integrate into our ProFound...
Why RCI Became the First in the State to Adopt ProFound AI as its Breast AI Solution for Mammography
Iowa’s largest radiology group, Radiology Consultants of Iowa (RCI), offers a wide range of imaging services for patients, including breast cancer screening. In addition to the mammograms done at their imaging center, which is accredited by the American College of Radiology (ACR) as a Breast Imaging Center of Excellence, RCI...
New Research Finds iCAD’s ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models
Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen hadalmost 20 times higher risk of developing breast cancer in the next year than the general risk population iCAD recently announced that promising clinical research supporting ProFound AI® Risk for Digital Breast Tomosynthesis (DBT)...